GLENMARK - Glenmark Pharmaceuticals

Glenmark Pharmaceuticals

GLENMARK · Pharma > Pharmaceuticals & Drugs · Chairman: Glenn Saldanha · MD: Glenn Saldanha · Listing date: Feb. 9, 2000 · Employees: 10964 · Mumbai · http://www.glenmarkpharma.com

Stock Price vs Company Growth

0.8%

2.1%

6.2%

6.5%

19.8%

81.9%

37.0%

10y

8.9%

all

10.1%

🤔 How to analyze this graph?

Last Traded Price

₹ 1,622 0.8%

1,447

1,830

Company Overview

Sales

12,248 Cr

Growth: 1.0%

Profit after Tax

-875 Cr

Growth: -33.3%

Large Cap

45,782 Cr

P/S: 3.7x

Industry P/S: 3.3x

Fundamentals

Sales (Cr)	₹ 12,248
Growth	1.0%
EBITDA	12.1%
P/S	3.7x
Dividend	0.3%
P/E	-45.0x
Book Value	₹ 303
PEG Ratio	-44.3x
ROE	-10.4%
P/B	5.4x

Shareholding Pattern

Institutions

Qualified Institutional Buyer

4.74 %

Hsbc Pooled Investment Fund - Hsbc Pooled Asia Pac

3.25 %

Hdfc Trustee Company Ltd. A/C Hdfc Growth Opportunities Fund

2.26 %

Ntasain Discovery Master Fund

2.05 %

Life Insurance Corporation Of India

1.76 %

Promoters

Saldanha Family Trust

45.45 %

Blanche Elizabeth Saldanha

0.39 %

Glenn Mario Saldanha

0.35 %

Cherylann Maria Pinto

0.27 %

Robin Joseph Pinto

0.18 %

Others

Ashish Dhawan

1.81 %

Iepf

0.08 %

Increase Decrease No change

Company Profile Detailed

The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Specialty Business: Drug Discovery: Glenmark’s ground-breaking drug discovery effort is primarily focused in the areas of inflammation [asthma/COPD, rheumatoid arthritis etc.], metabolic disorders [diabetes, obesity, etc.] and pain [neuropathic pain and inflammatory pain].

Belongs to (27 Indices) view more

Investors (108)

tata.bal...

robin.pi...

oppeheim...

Followers (36)

nitin2

keerthi

deepak